BMC Cancer (Mar 2023)

Impact of oral statin therapy on clinical outcomes in patients with cT1 breast cancer

  • Koji Takada,
  • Shinichiro Kashiwagi,
  • Nozomi Iimori,
  • Rika Kouhashi,
  • Akimichi Yabumoto,
  • Wataru Goto,
  • Yuka Asano,
  • Yukie Tauchi,
  • Tamami Morisaki,
  • Kana Ogisawa,
  • Masatsune Shibutani,
  • Hiroaki Tanaka,
  • Kiyoshi Maeda

DOI
https://doi.org/10.1186/s12885-023-10631-w
Journal volume & issue
Vol. 23, no. 1
pp. 1 – 14

Abstract

Read online

Abstract Purpose A previous meta-analysis examining the relationship between statin use and breast cancer reported that the inhibitory effect of statins on breast cancer may be more pronounced in early-stage cases. In this study, we aimed to investigate the effects of hyperlipidemia treatment at the time of breast cancer diagnosis and to examine its correlation with metastasis to axillary lymph nodes among patients with so-called cT1 breast cancer whose primary lesion was 2 cm or less and was pathologically evaluated by sentinel lymph node biopsy or axillary lymph node dissection. We also investigated the effects of hyperlipidemic drugs on the prognosis of patients with early-stage breast cancer. Methods After excluding cases that did not meet the criteria, we analyzed data from 719 patients who were diagnosed with breast cancer, with a primary lesion of 2 cm or less identified by preoperative imaging, and who underwent surgery without preoperative chemotherapy. Results Regarding hyperlipidemia drugs, no correlation was found between statin use and lymph node metastasis (p = 0.226), although a correlation was found between lipophilic statin use and lymph node metastasis (p = 0.042). Also, the disease-free survival periods were prolonged following treatment of hyperlipidemia (p = 0.047, hazard ratio: 0.399) and statin administration (p = 0.028, hazard ratio: 0.328). Conclusion In cT1 breast cancer, the results suggest that oral statin therapy may contribute to favorable outcomes.

Keywords